Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, ...

In February 2025, Belite completed a registered direct offering priced at the market, raising gross proceeds of $15 million, ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...